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Abstract
Introduction:  Coronary  artery  disease  is  becoming  the  leading  cause  of  death  in  women  in
Western  society.  However,  the  available  data  shows  that  women  are  still  underdiagnosed  and
undertreated  with  guideline-recommended  secondary  prevention  therapy,  leading  to  a  signifi-
cantly higher  rate  of  in-hospital  complications  and  in-hospital  mortality.
Objective:  The  main  objective  of  this  work  is  to  assess  the  approach  to  acute  coronary  syn-
drome (ACS)  in  Portugal,  including  form  of  presentation,  in-hospital  treatment  and  in-hospital
complications,  according  to  gender  and  in  three  different  periods.
Methods:  We  performed  an  observational  study  with  retrospective  analysis  of  all  patients
included between  2002  and  2019  in  the  Portuguese  Registry  of  Acute  Coronary  Syndromes
(ProACS), a  voluntary,  observational,  prospective,  continuous  registry  of  the  Portuguese  Society
of Cardiology  and  the  National  Center  for  Data  Collection  in  Cardiology.
Results:  A  total  of  49  113  patients  (34  936  men  and  14  177  women)  were  included.  Obe-
sity, hypertension,  diabetes  (p<0.001  for  all)  and  dyslipidemia  (p  =  0.022)  were  all  more
prevalent in  women,  who  were  more  frequently  admitted  for  non-ST  segment  elevation
ACS (p<0.001),  and  more  frequently  presented  with  atypical  symptoms.  Women  had  more
time until  needle  and  until  reperfusion,  which  is  less  accessible  to  this  gender  (p<0.001).
During hospitalization,  women  had  a  significantly  higher  risk  of  in-hospital  mortality  (OR
1.94 [1.78-2.12],  p<0.001),  major  bleeding  (OR  1.53  [1.30-1.80],  p<0.001),  heart  failure
01),  atrial  fibrillation  (OR  1.55  [1.36-1.77],  p<0.001),  mechanical
8-2.53],  p<0.001),  cardiogenic  shock  (OR  1.71  [1.57-1.87],  p<0.001)
.62],  p<0.001).  Women  were  more  likely  to  have  a  normal  coronary(OR 1.87  [1.78-1.97],  p<0.0
complications  (OR  2.12  [1.7
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angiogram  or  coronary  lesions  with  <50%  luminal  stenosis  (p<0.001  for  both),  and  thus  a  final
diagnosis other  than  ACS.  Both  during  hospitalization  and  at  hospital  discharge,  women  were
less likely  to  receive  guideline-recommended  secondary  prevention  therapy.
Conclusion:  In  women  admitted  for  ACS,  revascularization  strategies  are  still  underused,  as
is guideline-recommended  secondary  prevention  therapy,  which  may  explain  their  higher  inci-
dence of  in-hospital  complications  and  higher  unadjusted  mortality.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Entender  o corac¸ão da  mulher:  lic¸ões  de  14  177  mulheres  com  síndromas  coronárias
agudas
Resumo
Introduc¸ão:  A  doenc¸a  arterial  coronária  está-se  a  tornar  a  principal  causa  de  morte  no  mundo
ocidental no  género  feminino.  Contudo,  os  dados  de  que  dispomos  mostram  que  as  mulheres  são
ainda subdiagnosticadas  e  subtratadas  com  as  terapias  de  prevenc¸ão  secundária  recomendadas,
levando a  taxas  significativamente  mais  altas  de  complicac¸ões  intra-hospitalares  e  mortalidade
intra-hospitalar.
Objetivo: Avaliar  a  abordagem  nacional  às  síndromas  coronárias  agudas,  incluindo  forma  de
apresentac¸ão, tratamento  intra-hospitalar  e  complicac¸ões  intra-hospitalares,  de  acordo  com  o
género e  em  três  períodos  distintos.
Métodos:  Estudo  observacional  com  análise  retrospetiva  de  todos  os  doentes  incluídos  entre
2002 e  2019  no  Registo  Nacional  de  Síndromas  Coronárias  Agudas  (RNSCA),  um  registo  volun-
tário, observacional,  prospetivo  e  contínuo  da  Sociedade  Portuguesa  de  Cardiologia  e  do  Centro
Nacional  de  Colec¸ão  de  Dados  em  Cardiologia.
Resultados:  Foram  incluídos  49  113  doentes  (34  936  homens  e  14  177  mulheres).  Obesidade,
hipertensão  arterial,  diabetes  mellitus  (p  <  0,001  para  todos)  e  dislipidémia  (p  =  0,022)  foram
mais prevalentes  nas  mulheres,  que  são  mais  frequentemente  admitidas  por  síndroma  coronária
aguda sem  supradesnivelamento  do  segmento  ST  (p  <  0,001)  e  mais  frequentemente  se  apresen-
tam com  sintomas  atípicos.  As  mulheres  têm  tempos  mais  longos  até  agulha  e  até  reperfusão,
esta última  menos  frequente  neste  género  (p  <  0,001).  Durante  hospitalizac¸ão,  as  mulheres
têm um  risco  significativamente  maior  de  mortalidade  intra-hospitalar  (OR  1,94  [1,78;2,12],  p
< 0,001),  hemorragia  major  (OR  1,53  [1,30;1,80],  p  <  0,001),  insuficiência  cardíaca  (OR  1,87
[1,78;1,97],  p  <  0,001),  fibrilhac¸ão  auricular  (OR  1,55  [1,36;1,77],  p  <  0,001),  complicac¸ões
mecânicas  (OR  2,12  [1,78;2,53],  p  <  0,001),  choque  cardiogénico  (OR  1,71  [1,57;1,87],  p  <
0,001) e  acidente  vascular  cerebral  (OR  2,15  [1,76;2,62],  p  <  0,001).  É  mais  provável  que  as
mulheres tenham  uma  coronariografia  normal  ou  lesão  coronárias  com  estenose  luminal  <  50%
(p <  0,001  para  ambos)  e,  assim,  um  diagnóstico  final  alternativo  a  síndroma  coronária  aguda.
Seja durante  hospitalizac¸ão  ou  à  alta  hospitalar,  é  menos  provável  que  as  mulheres  recebam  as
terapias de  prevenc¸ão  secundária  recomendadas.
Conclusão:  Em  mulheres  admitidas  com  síndroma  coronária  aguda  as  estratégias  de
revascularizac¸ão são  subutilizadas,  assim  como  as  terapias  de  prevenc¸ão  secundária  recomen-
dadas, podendo  justificar  a  maior  incidência  de  complicac¸ões  intra-hospitalares  e  maior
mortalidade  não  ajustada.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´ um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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istorically,  coronary  artery  disease  (CAD)  has  been  per-Please  cite  this  article  in  press  as:  Roque  D,  et  al.  Understandin
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eived  as  a  disease  of  men,  rarely  presenting  in  women,
hich  leads  to  under-appreciation  by  health  professionals
f  symptoms  in  women.1 However,  this  historical  view  is  no
onger  correct,  since  CAD  is  now  becoming  the  leading  cause
a
g
t
if  death  in  women  in  Western  society,  overtaking  uterine
ancer,  breast  cancer  and  peripartum  mortality.2 In  Europe,
round  23%  of  all  deaths  in  females  are  due  to  CAD,  and,
lthough  the  number  of  women  diagnosed  with  CAD  hasg  a  woman’s  heart:  Lessons  from  14  177  women  with  acute
.1016/j.repc.2020.03.002
rown  substantially  in  the  last  few  years  compared  to  men,
he  disease  is  still  clearly  underdiagnosed  and  undertreated
n  women,  who  have  less  access  to  revascularization  and
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optimal  medical  therapy.2 In  addition,  although  in  recent
decades  there  has  been  a  significant  reduction  in  mortality
from  myocardial  infarction  (MI),  mainly  in  those  aged  over
65  years,  there  is  evidence  that  this  improvement  in  inci-
dence  and  mortality  is  slowing  down,  especially  in  younger
women  aged  under  55  years.3
The  main  objective  of  this  work  is  to  assess  the  approach
to  acute  coronary  syndrome  (ACS)  in  Portugal,  including
form  of  presentation,  in-hospital  treatment  and  in-hospital
complications,  according  to  gender  and  in  three  different
time  periods:  2002-2010,  2011-2015,  and  2016-2019,  using
data  from  the  Portuguese  Registry  on  Acute  Coronary  Syn-
dromes  (ProACS)  of  the  Portuguese  Society  of  Cardiology  and
the  National  Center  for  Data  Collection  in  Cardiology.
Methods
We  performed  an  observational  study  with  retrospective
analysis  of  all  patients  included  in  the  ProACS  between  2002
and  May  15,  2019  (n=49  247).
Population
The  ProACS  is  a  voluntary,  observational,  prospective,  con-
tinuous  performed  through  the  CardioBase  (InforTUCANO
SI),  which  includes  all  patients  aged  ≥18  years  of  age  with
a  diagnosis  of  ACS  of  less  than  48  hours  duration,  excluding
patients  with  type  2,  4  or  5  MI.  The  inclusion  and  exclusion
criteria  and  the  data  collection  form  have  been  published
elsewhere.4,5 The  three  periods  studied  (2002-2010,  2011-
2015,  and  2016-2019)  were  chosen  taking  into  consideration
the  release  of  new  guidelines  for  the  treatment  of  patients
with  ST-elevation  myocardial  infarction  (STEMI)  and  non-ST-
elevation  myocardial  infarction.
The  population  was  characterized  in  demographic  and
clinical  terms,  including  assessment  of  traditional  cardio-
vascular  risk  factors,  cardiovascular  and  non-cardiovascular
history,  description  of  the  acute  episode  (including  main
symptom,  physical  examination,  electrocardiogram  and
laboratory  tests),  therapy  (during  hospitalization  and  at  hos-
pital  discharge),  timings  (such  as  door-to-balloon  time),
reperfusion  strategy,  coronary  angiography  results  and
complications.
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The  groups  of  men  and  women  were  characterized  according
to  continuous  and  categorical  variables,  continuous  varia-
bles  being  expressed  as  sample  mean  and  standard  deviation
u
h
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Table  1  Age  of  the  population  (2002-May  2019).
Mean  <45  years  
Total  67±13  6.20%  
Men (n=34  936)  64±13  7.40%  
Women
(n=14 177)
72±12  3%  
p <0.001  <0.001   PRESS
h  acute  coronary  syndrome  3
r  median  and  interquartile  range,  and  categorical  variables
s  absolute  and  relative  frequencies.  Comparisons  between
roups  regarding  categorical  variables  were  conducted  using
he  chi-square  test  or  Fisher’s  test.  Means  of  continuous
ariables  were  compared  using  t  tests  whenever  possible;
therwise,  the  Mann-Whitney  U  test  was  used  to  compare
he  medians.  When  three  groups  were  analyzed  together,
he  chi-square  test  or  the  Monte  Carlo  simulation  test  for
he  chi-square  statistic  was  used  for  categorical  variables
nd  analysis  of  variance  or  the  Kruskal-Wallis  test  was  used
or  continuous  variables.  The  statistical  analysis  was  per-
ormed  using  IBM  SPSS  19.0®, and  a  significance  level  of  5%
as  assumed  for  testing  the  hypothesis.
esults
opulation  characteristics
fter  exclusion  of  134  patients  due  to  missing  data,  a  total
f  49  113  patients  were  included  for  analysis,  divided  by
ender  and  in  three  different  periods.
Most  patients  were  included  between  2002  and  2010
n=30  046),  with  a  progressive  decrease  in  the  number  of
ntil  only  5287  patients  included  between  2016  and  May
019.  The  number  of  men  included  was  considerably  higher
n  all  three  periods  (20  995  vs.  9051  in  2002-2010;  10  020  vs.
760  in  2011-2015;  and  3921  vs.  1366  in  2016-2019).  We  are
nable  to  determine  whether  this  is  due  to  a  smaller  number
f  hospital  admissions  due  to  ACS  in  women  or  to  a  smaller
umber  of  records  for  women.  The  mean  age  of  the  popula-
ion  was  67±13  years,  with  women  being,  on  average,  eight
ears  younger  than  men,  and  being  the  dominant  gender  in
he  younger  age  ranges  (<45  years  and  45-64  years),  a  ten-
ency  that  was  reversed  in  those  aged  ≥65  years  (Table  1).
Regarding  classical  cardiovascular  risk  factors,  significant
ifferences  were  found  in  obesity,  hypertension,  diabetes
nd  dyslipidemia,  all  of  which  were  more  prevalent  in
omen  (Tables  2  and  3).  Furthermore,  between  2002  and
019  there  was  a  clear  tendency  towards  a  greater  preva-
ence  of  diabetes,  dyslipidemia,  and  smoking  among  women
dmitted  to  hospital  due  to  ACS,  with  only  slight  improve-
ents  in  hypertension  and  obesity.
The  same  pattern  was  seen  in  men,  except  for  a  slight,
on-significant,  improvement  in  hypertension  and  dyslipi-
emia  (Table  3).  Stable  angina  prior  to  hospital  admission
as  more  prevalent  in  women,  as  was  a history  of  heart  fail-g  a woman’s  heart:  Lessons  from  14  177  women  with  acute
.1016/j.repc.2020.03.002
re,  significant  valve  disease,  and  stroke,  while  a  personal
istory  of  MI,  percutaneous  coronary  intervention  (PCI)  or
oronary  artery  bypass  grafting  (CABG)  was  more  common
n  men  (Table  2).
45-64  years  65-74  years  ≥75  years
35.30%  26.40%  32.10%
41.30%  26.20%  25.10%
20.60%  26.90%  49.50%
<0.001  <0.001  <0.001
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Table  2  Cardiovascular  risk  factors  and  other  personal  history  (2002-May  2019).
Men  (n=34  936)  Women  (n=14  177)  p  OR  (95%  CI)
Obesity  20.40%  (n=30  368) 23.80%  (n=11  577)  <0.001  1.22  (1.16-1.28)
Smoking 32.60%  (n=34  865)  8.50%  (n=14  140)  <0.001  0.19  (0.18-0.20)
Hypertension  60.40%  (n=34  698)  75.90%  (n=14  129)  <0.001  2.06  (1.97-2.16)
Diabetes 26.00%  (n=34  694)  35.9%  (n=14  099)  <0.001  1.59  (1.53-1.66)
Dyslipidemia  49.40%  (n=34  301)  50.60%  (n=13  941)  0.022  1.05  (1.01-1.09)
Family history  of  CADa 7.20%  (n=12  810)  6.40%  (n=4700)  0.063  0.88  (0.77-1.01)
PAD 4.70%  (n=34  784)  3%  (n=14  085)  <0.001  0.62  (0.56-0.69)
Kidney diseasea 5.90%  (n=14  270)  6.90%  (n=5264)  0.013  1.17  (1.03-1.33)
COPDa 5.40%  (n=14  326) 4.90%  (n=5309) 0.143  0.90  (0.78-1.04)
Stable angina 23.80%  (n=34  838) 29.10%  (n=14  114) <0.001  1.32  (1.26-1.37)
MI 20.10%  (n=34  810) 16.20%  (n=14  111) <0.001  0.77  (0.73-0.81)
PCI 11.80%  (n=34  838)  7.50%  (n=14  133)  <0.001  0.60  (0.56-0.65)
CABG 5%  (n=34  872)  3.10%  (n=14  145)  <0.001  0.61  (0.55-0.68)
Pacemaker/ICDa 2.10%  (n=14  422)  1.70%  (n=5330)  0.127  0.83  (0.66-1.05)
Valve diseasea 2.60%  (n=14  395)  5%  (n=5302)  <0.001  1.94  (1.66-2.28)
HFa 5%  (n=14  488)  8%  (n=5348)  <0.001  1.65  (1.46-1.87)
Stroke 6.80%  (n=34  866) 8.20%  (n=14  126)  <0.001  1.22  (1.13-1.31)
Cancer 4.70%  (n=14  083)  5.40%  (n=5214)  0.046  1.16  (1.00-1.33)
Bleedinga 1.10%  (n=13  734) 3.90%  (n=5096)  <0.001  3.50  (2.83-4.34)
a variable included only after October 2010.
CABG: coronary artery bypass grafting; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; ICD: implantable
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Women  were  also  more  likely  to  fulfill  criteria  for  a  diagnosiscardioverter-defibrillator; HF: heart failure; MI: myocardial infa
intervention.
ospital  admission  and  timings
ur  analysis  by  the  three  periods  and  by  the  overall  study
eriod  reveals  that  compared  with  men,  women  were  more
requently  admitted  with  a  diagnosis  of  non-ST-elevation
CS,  including  non-ST-elevation  MI  and  unstable  angina.
lthough  the  most  common  symptom  at  presentation  in  both
exes  was  chest  pain,  women  more  frequently  presented
ith  symptoms  interpreted  as  equivalent,  such  as  dyspnea,
atigue  or  syncope;  in  addition,  fewer  women  reported  chest
ain  at  admission.  Both  of  these  are  potential  reasons  for  a
elay  in  diagnosis  (Table  4).
Regarding  timings  between,  first  medical  contact  (FMC)
r  arrival  at  the  door,  there  are  several  interesting  findings.
n  the  overall  period  considered,  in  all  the  timings  analyzed
or  patients  with  STEMI  (Table  5),  times  to  needle  and  to
eperfusion  were  longer  in  women  (whether  reperfusion  is
efined  as  time-to-balloon  or  wire-crossing,  and  whether  the
tarting  point  is  defined  as  symptom  onset,  FMC  or  arrival  at
he  door).  As  shown  in  Table  6,  however,  there  was  no  con-
inuous  or  consistent  improvement  over  the  periods  when
ompared  within  the  same  gender;  for  example,  regard-
ng  FMC-to-needle  or  FMC-to-reperfusion  times,  the  shortest
imes  were  in  the  period  2002-2010  for  both  sexes  (except
or  FMC-to-needle  time  in  women,  for  which  the  shortest
ime  was  in  the  period  2016-2019).  Also,  when  consider-
ng  times  starting  at  symptom  onset,  the  same  pattern  is
bserved,  with  the  longest  delays  in  the  more  recent  peri-
ds,  with  the  exception  of  symptom  onset-to-needle  timePlease  cite  this  article  in  press  as:  Roque  D,  et  al.  Understandin
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n  men,  for  which  an  improvement  was  noted,  and  symptom
nset-to-balloon  in  women,  for  which  there  are  no  signifi-
ant  differences.
o
p
(n; PAD: peripheral arterial disease; PCI: percutaneous coronary
The  same  gender  differences  are  seen  in  the  timings  for
ll  patients  with  ACS  (Table  7),  with  women  having  signifi-
antly  longer  times  than  men.
ospitalization
ased  on  the  available  clinical,  laboratory,  electrocar-
iographic  and  risk  stratification  data,  women  had  a
ignificantly  higher  risk  of  in-hospital  death  than  men,
ith  significantly  higher  GRACE  scores  (158.4±41.2  vs.
45.4±38.9,  p<0.001),  which  represents  a  mean  mortal-
ty  risk  of  20-30%  (mortality  risk  with  a  GRACE  score  of
50-173).  Furthermore,  women  were  also  at  greater  risk
f  major  bleeding  during  hospital  stay,  as  indicated  by  a
ean  CRUSADE  score  of  39.6±15.3  (vs.  22.4±14.6  in  men,
<0.001),  representing  an  8.6%  risk  (moderate)  compared
o  men,  whose  risk  was  estimated  to  be  low  (5.5%).  In
ddition,  as  an  indicator  of  severity  of  heart  failure  and
isk  of  30-day  mortality  after  ACS,  women  were  also  less
ikely  to  be  in  Killip  class  I  at  admission  or  during  hospi-
al  stay,  the  difference  being  statistically  significant  in  all
illip  classes,  attributing  greater  severity  to  the  female  gen-
er  (Table  8).  Women  were  also  more  likely  to  develop
trial  fibrillation  (8.8%  vs.  6.3%,  p<0.001),  to  have  acute
idney  injury  or  creatinine  >2  mg/dl  (12.5%  vs.  10.3%),  and
o  have  anemia  (with  statistically  lower  mean  hemoglobin),
s  well  as  hemoglobin  below  10  g/dl  and  8  g/dl  (16.5%  and
.6%  vs.  3.6%  and  1.5%,  respectively,  p<0.001  for  both).g  a  woman’s  heart:  Lessons  from  14  177  women  with  acute
.1016/j.repc.2020.03.002
f  diabetes  (glycated  hemoglobin  >6.5%)  (38.1%  vs.  30.7%,
<0.001),  and  to  have  higher  brain  natriuretic  peptide  levels
Table  8).
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Table  3  Changes  in  classical  cardiovascular  risk  factors.
Men  Women
2002-2010  2011-2015  2015-  May  2019 p  2002-2010  2011-2015  2015-  May  2019 p
Obesity  19.0%
(n=18  279)
21.0%
(n=8733)
23.8%
(n=3356)
<0.001  23.0%
(n=7386)
25.9%
(n=3088)
23.1%
(n=1103)
0.007
Hypertension 57.1%
(n=20  975)
65.7%
(n=9836)
65.1%
(n=3887)
<0.001  73.7%
(n=9046)
80.8%
(n=3726)
77.5%
(n=1357)
<0.001
Dyslipidemia 44.3%
(n=20  930)
57.9%
(n=9510)
56.2%
(n=3861)
<0.001  45.4%
(n=9021)
60.0%
(n=3571)
60.3%
(n=1349)
<0.001
Smoking 31.8%
(n=20  983)
33.7%
(n=9969)
34.6%
(n=3913)
<0.001  6.0%
(n=9044)
11.4%
(n=3735)
16.9%
(n=1361)
<0.001
Diabetes 24.1%
(n=20  969)
28.2%
(n=9831)
30.7%
(n=3894)
<0.001  34.8%
(n=9042)
37.3%
(n=3698)
39.1%
(n=1359)
<0.001
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Table  4  Diagnosis.  main  symptom  and  pain  characteristics  at  hospital  presentation.
2002-2010  2011-2015  2016-2019  2002-2019
Men
(n=20  995)
Women
(n=9051)
Men
(n=10  020)
Women
(n=3760)
Men
(n=3921)
Women
(n=1366)
Men
(n=34  936)
Women
(n=14  177)
p
Diagnosis
NSTEMI  39.8%
(n=8357)
45.4%
(n=4105)
46.8%
(n=4687)
50.5%
(n=1900)
50.1%
(n=1964)
53.5%
(n=731)
43%
(n=15  008)
47.5%
(n=6736)
<0.001
STEMI 45.6%
(n=9574)
37.2%
(n=3371)
42.4%
(n=4248)
37.6%
(n=1412)
43.2%
(n=1695)
39.2%
(n=535)
44.4%
(n=15  517)
37.5%
(n=5318)
<0.001
UA 11.7%
(n=2458)
12.4%
(n=1122)
7.8%
(n=785)
6.9%
(n=259)
3.8%
(n=148)
3.7%
(n=50)
9.7%
(n=3391)
10.1%
(n=1431)
0.191
Othera 2.9%
(n=606)
5%
(n=453)
3%
(n=300)
5%
(n=189)
2.9%
(n=114)
3.7%
(n=50)
2.9%
(n=1020)
4.9%
(n=692)
<0.001
Main  symptom
Chest  pain  99.7%
(n=19  306)
99.6%
(n=8127)
92.6%
(n=9280)
86.1%
(n=3293)
92.7%
(n=3633)
88.4%
(n=1208)
96.8%
(n=32  219)
94.7%
(n=12  574)
<0.001
Dyspnea 0.1%
(n=29)
0.2%
(n=17)
3.2%
(n=323)
6.5%
(n=244)
3.2%
(n=125)
5.6%
(n=76)
1.4%
(n=477)
2.5%
(n=377)
<0.001
Fatigue  0%
(n=2)
0%
(n=4)
0.5%
(n=51)
1%
(n=37)
0.7%
(n=26)
0.7%
(n=10)
0.2%
(n=79)
0.4%
(n=51)
0.007
Syncope  0%
(n=9)
0%
(n=4)
1.4%
(n=142)
2.6%
(n=97)
1.3%
(n=51)
2.2%
(n=30)
0.6%
(n=202)
1%
(n=131)
<0.001
Cardiac  arrest  0%
(n=3)
0%
(n=0)
0.5%
(n=47)
0.5%
(n=19)
0.8%
(n=31)
0.7%
(n=10)
0.2%
(n=81)
0.2%
(n=29)
0.616
Other  0%
(n=7)
0.1%
(n=6)
1.8%
(n=177)
3.3%
(n=124)
1.4%
(n=55)
2.3%
(n=32)
0.7%
(n=239)
1.2%
(n=162)
<0.001
Pain  characteristics
Started  at  rest  87.4%
(n=16843)
86.4%
(n=7017)
89.5%
(n=7715)
90%
(n=2712)
90.9%
(n=3060)
91.7%
(n=1031)
88.3%
(n=27618)
87.8%
(n=10760)
0.111
Present  at
admission
58.8%
(n=11346)
56.4%
(n=4577)
66.7%
(n=5705)
64.7%
(n=1932)
60.8%
(n=2041)
59.9%
(n=672)
61.2%
(n=19092)
58.7%
(n=7181)
<0.001
Episodic  30.4%
(n=5862)
32.3%
(n=2623)
41.5%
(n=3499)
42.1%
(n=1244)
37.5%
(n=1244)
35.4%
n=395)
34.2%
(n=10605)
35%
(n=4262)
0.11
a Myocardial infarction with atypical electrocardiographic presentation (bundle branch block or ventricular pacing).
NSTEMI: non-ST-segment myocardial infarction; STEMI: ST-elevation myocardial infarction; UA: unstable angina.
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Table  5  Changes  in  timings  starting  at  symptom  onset,  arrival  at  the  door  and  first  medical  contact  for  patients  admitted  with  ST-elevation  myocardial  infarction.
2002-2010  2011-2015  2016-May  2019 2002-May  2019
Men
(n=9574)
Women
(n=3371)
Men
(n=4248)
Women
(n=1412)
Men
(n=1695)
Women
(n=535)
Men
(n=15  517)
Women
(n=5318)
p
Symptom  onset-wire  crossing,
min
285;  214
[145;360]
334;  270
[175;420]
317;  237
[162;380]
361;  285
[190;465]
331;  255
[167;400]
363;270
[185;448]
301;  228
[150;369]
346;  275
[180;430]
<0,001
Symptom onset-needle,  min 263;  200
[135;330]
322;  270
[165;410]
236;  185
[120;270]
249;  195
[150;300]
253;  182,5
[130;330]
361;  310
[160,5;487,5]
261;  200
[130;330]
317;  260
[165;405]
<0,001
Symptom onset-balloon,  min 316;  240
[160;395]
350;280
[189;425]
324;240
[165;390]
369;  297
[197;480]
333;  259
[170;402]
363;  270
[185;448]
323;  240
[165;395]
361;  284
[190;452]
<0,001
FMC-to-wire crossing,  min 84;  45  [20;90] 101;  55
[25;112]
143;  109
[70;166]
171;  124
[81;200]
142;  107
[53;174]
162;  115
[71;189]
110;  71
[30;135]
131;  85
[38;155]
<0,001
FMC-to-needle,  min  74;  37  [15;77]  89;  46  [20;96]  88;  60  [36;104]  90;  77
[43,5;107,5]
120;  95,5
[52,5;126]
58;  62
[35,5;80]
75;  39  [17;80]  89;  48  [20;97]  <0,001
FMC-to-balloon, min  96;  55  [28;107]  115;  62,5
[30;125]
147;  112
[73;169]
176;  128
[84;205]
142;107
[53;175]
164;  115
[72;191]
127;  90
[45;153]
151;  105
[57;178]
<0,001
Door-to-wire crossing,  min  110;  58
[25;120]
125;  66,5
[30;147]
108;  64
[27;135]
132;  83,5
[35;160]
107;  54
[20;135]
124;  67
[26;150]
109;  60
[25;128]
127;72  [30;151]  <0,001
Door-needle, min  99;  46  [20;105]  115;  58
[26;130]
73;  39  [20;75]  64;  48  [21;92]  85;  47,5
[30;96]
49;  40,5
[15;80]
97;  45  [20;103]  111;  56
[25;122]
<0,001
Door-to-balloon,  min 123;  71
[31;141]
136;  85
[37,5;163]
111;68  [27;140]  138;  87
[40;171]
107;  54
[19;136]
126;  67
[26;153]
114;  66
[28;140]
135;  83
[35;164]
<0,001
Values are mean; median [25th;75th percentile].
FMC: first medical contact.
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Table  6  Changes  in  timings  starting  at  symptom  onset,  arrival  at  the  door  and  first  medical  contact  for  patients  admitted  with  ST-elevation  myocardial  infarction,  according
to gender.
2002-2010  2011-2015  2016-May  2019  2002-May  2019
Men
(n=20  995)
Women
(n=9051)
Men
(n=10  020)
Women
(n=3760)
Men
(n=3921)
Women
(n=1366)
Men
(n=34  936)
Women
(n=14  177)
p
Symptom
onset-to-FMC,  min
369;  158.5
[80;337.5]
453;  191
[86;399]
351;  147
[75;321]
394;  175
[90;375]
336;  156
[90;310]
452;  180
[93;401]
347;  150
[79;320]
412;  179
[90;381]
<0.001
Symptom
onset-to-door, min
703;  254
[120;716]
847;  350
[148;900]
462;  210
[111;510]
531;  266
[125;619]
489;  249
[1;570]
629;  324
[145;712]
610;  240
[119;625]
743;  318
[140;781]
<0.001
FMC-to-door, min  217;  105
[47;300]
418;  140.5
[56;431]
217;  106
[51;254]
261;  147.5
[62;360]
264;  161
[63;395.5]
321;  210.5  [74;
438]
232;  119
[54;307]
287;  168
[65;400]
<0.001
Values are mean; median [25th;75th percentile].
FMC: first medical contact.
Table  7  Changes  in  timings  starting  at  symptom  onset  and  first  medical  contact  for  all  patients  with  acute  coronary  syndrome.
2002-2010  2011-2015  2016-May  2019  2002-May  2019
Men
(n=20  995)
Women
(n=9051)
Men
(n=10  020)
Women
(n=3760)
Men
(n=3921)
Women
(n=1366)
Men
(n=34  936)
Women
(n=14  177)
p
Symptom
onset-to-FMC,  min
369;  158.5
[80;337.5]
453;  191
[86;399]
351;  147
[75;321]
394;  175
[90;375]
336;  156
[90;310]
452;  180
[93;401]
347;  150
[79;320]
412;  179
[90;381]
<0.001
Symptom
onset-to-door, min
703;  254
[120;716]
847;  350
[148;900]
462;  210
[111;510]
531;  266
[125;619]
489;  249
[1;570]
629;  324
[145;712]
610;  240
[119;625]
743;  318
[140;781]
<0.001
FMC-to-door, min 217;  105
[47;300]
418;  140.5
[56;431]
217;  106
[51;254]
261;  147.5
[62;360]
264;  161
[63;395.5]
321;  210.5  [74;
438]
232;  119
[54;307]
287;  168
[65;400]
<0.001
Values are mean; median [25th;75th percentile].
FMC: first medical contact.
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Understanding  a  woman’s  heart:  Lessons  from  14  177  wome
Analysis  of  reperfusion  therapies  in  the  overall  ACS  pop-
ulation  shows  that  although  their  use  increased  over  the
three  study  periods,  in  general  women  had  less  access  to
both  invasive  and  pharmacologic  reperfusion  therapies  than
men  (p<0.001).  When  reperfusion  was  performed,  no  sig-
nificant  differences  were  observed  between  periods  or  the
overall  period  analyzed,  with  less  use  of  fibrinolysis  and
a  clear  dominance  of  primary  angioplasty.  For  the  latter,
a  difference  can  be  seen  regarding  vascular  access,  with
radial  access  used  less  frequently  in  women  than  in  men
(p<0.001)  (Table  9).  Women  were  more  likely  to  have  a
normal  coronary  angiogram  or  coronary  lesions  with  <50%
luminal  stenosis,  and  thus  a  final  diagnosis  other  than  ACS.
Women  were  also  less  likely  to  have  multivessel  disease
(two  or  three  vessels);  however,  the  culprit  lesion  was  more
difficult  to  identify  in  women  (18.1%  vs.  16.2%,  p<0.001)
(Table  9).  Regarding  pharmacological  therapy  during  hos-
pitalization,  the  situation  was  similar,  women  being  less
likely  to  receive  guideline-recommended  therapy,  including
aspirin,  P2Y12 inhibitors,  beta-blockers,  and  statins;  how-
ever,  based  on  the  available  data,  it  is  impossible  to  be
sure  whether  this  difference  is  due  to  there  being  more
potential  diagnoses  other  than  ACS  in  women  compared  with
men.  Women  were  more  likely  to  receive  more  nitrates,  min-
eralocorticoid  receptor  antagonists,  diuretics,  amiodarone,
inotropes,  insulin,  and  oral  antidiabetic  therapy  duringPlease  cite  this  article  in  press  as:  Roque  D,  et  al.  Understandin
coronary  syndrome.  Rev  Port  Cardiol.  2020.  https://doi.org/10
hospitalization,  which  can  be  interpreted  as  indicators  of
severity.  The  same  tendency  can  be  seen  at  hospital  dis-
charge,  when  women  were  less  likely  to  be  prescribed
Table  8  Parameters  assessed  during  hospitalization.
2002-May  2019
Men
(n=34  936)
GRACE  score,  mean  ±  SDa 145.4±38.9  
CRUSADE score,  mean  ±  SDa 22.4±14.6  
HR, bpm,  mean  ±  SD  77±19  
SBP, mmHg,  mean  ±  SD  140±29  
Killip class I  85.2%  (28966)  
II 9.4%  (3203)  
III 3.7%  (1245)  
IV 1.7%  (578)  
Rhythma Sinus  91.8%  (13360)  
AF 6.3%  (919)  
IVCDa LBBB  7.7%  (1194)  
RBBB 6.4%  (986)  
Peak creatinine,
mg/dla
Mean  ±  SD  1.4±1.2  
>2 10.3%  (1076)  
Min. Hb,  g/dla Mean  ±  SD  13±1.9  
<10 6.5%  (707)  
<8 1.5%  (160)  
HbA1c >6.5%a 30.7%  (1327)  
BNP, pg/mla Mean  ±  SD 369±698  
>400 23.8%  (1064)  
LDL, mg/dla Mean  ±  SD  115±40  
a variable included only after October 2010.
AF: atrial fibrillation; bpm: beats per minute; BNP: brain natriuretic pe
hemoglobin; HR: heart rate; IVCD: intraventricular conduction delay; LB
minimum; N/A: not applicable; OR: odds ratio; RBBB: right bundle bra
D
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h  acute  coronary  syndrome  9
ntiplatelet  therapy  with  aspirin  or  P2Y12 inhibitors,  beta-
lockers,  and  statins.  On  the  other  hand,  women  were  more
ikely  to  receive  vitamin  K  antagonists,  mineralocorticoid
eceptor  antagonists,  diuretics,  amiodarone,  insulin  and  oral
ntidiabetic  therapy  as  outpatients  (Table  10).
ardiovascular  events  and  complications
n  this  study,  women  were  at  greater  risk  for  ACS-
ssociated  complications  during  hospitalization,  with  a
ignificantly  higher  prevalence  of  development  of  heart
ailure  (p<0.001),  cardiogenic  shock  (p<0.001),  mechanical
omplications  (p<0.001)  and  need  for  non-invasive  ventila-
ion  (p<0.001),  arrhythmic  events  including  atrial  fibrillation
p<0.001),  atrioventricular  block  and  need  for  temporary
acing  (p<0.001  for  both)  and  cardiac  arrest  (p=0.03),
schemic  and  bleeding  events  including  stroke  (p<0.001),
ajor  bleeding  (p<0.001),  and  need  for  blood  transfusion
p<0.001)  (Table  11).  Left  ventricular  ejection  fraction  did
ot  differ  significantly  between  groups,  even  when  divided
nto  quartiles.
Unadjusted  in-hospital  mortality  was  significantly  higher
n  women,  who  had  a  1.9-fold  greater  risk  of  dying  during
ospitalization  (Table  11).g  a woman’s  heart:  Lessons  from  14  177  women  with  acute
.1016/j.repc.2020.03.002
Women
(n=14  177)
p  OR  (95%  CI)
158.4±41.2  <0.001  N/A
39.6±15.3  <0.001  N/A
81±21  <0.001  N/A
142±32  <0.001  N/A
75.3%  (10323)  <0.001  0.53  [0.50;0.55]
15.8%  (2166)  <0.001  1.80  [1.70;1.91]
6.2%  (852)  <0.001  1.74  [1.59;1.91]
2.7%  (374)  <0.001  1.62  [1.42;1.85]
89.1%  (4792)  <0.001  0.73  [0.66;0.81]
8.8%  (474)  <0.001  1.43  [1.28;1.61]
14.1%  (835)  <0.001  1.95  [1.78;2.14]
4.4%  (260)  <0.001  0.67  [0.58;0.77]
1.3±1.2  <0.001  N/A
12.5%  (482)  <0.001  1.24  [1.10;1.39]
11.4±1.7  <0.001  N/A
16.5%  (669)  <0.001  2.86  [2.56;3.20]
3.6%  (147)  <0.001  2.54  [2.02;3.18]
38.1%  (631)  <0.001  N/A
612±906  <0.001  N/A
39.2%  (709)  <0.001  2.07  [1.84;2.33]
114±41  0.462  N/A
ptide; CI: confidence interval; Hb: hemoglobin; HbA1c: glycated
BB: left bundle branch block; LDL: low-density lipoprotein; Min.:
nch block; SBP: systolic blood pressure; SD: standard deviation.
iscussion
ardiovascular  disease  (CVD)  is  the  leading  cause  of  death
n  both  sexes  worldwide.  Each  year,  according  to  the  2017
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Table  9  Reperfusion  therapy  and  coronary  angiography  findings.
2002-2010  2011-2015  2016-2019  2002-2019
Men
(n=20  995)
Women
(n=9051)
Men
(n=10  020)
Women
(n=3760)
Men
(n=3921)
Women
(n=1366)
Men
(n=34  936)
Women
(n=14  177)
p
Reperfusion
therapy
70.7%
(n=6765)
57.9%(n=1952)  84.7%
(n=3596)
74.9%
(n=1058)
83.1%
(n=1408)
79.1%
(n=423)
75.8%
n=11  769)
64.6%
(n=3433)
<0.001
Type of  reperfusion  therapy
Fibrinolysis  58.1%
(n=3895)
57.1%
(n=1107)
7.8%
(n=281)
7.9%
(n=84)
2.6%
(n=37)
1.9%
(n=8)
36%
(n=4213)
35%
(n=1199)
0.322
PCI  41.9%
(n=2813)
42.9%
(n=833)
92.2%
(n=3315)
92.1%
(n=974)
97.4%
(n=1371)
98.1%
(n=415)
64%
(n=7499)
65%
(n=2222)
0.322
Arterial  accessa
Femoral  49.1%
(n=264)
49.8%
(n=106)
23%
(n=1992)
28.9%
(n=850)
11.2%
(n=361)
15.6%
(n=166)
21%
(n=2617)
26.6%
n=1122)
<0.001
Radial  50.9%
(n=274)
50.2%
(n=107)
77%
(n=6684)
71.1%
(n=2096)
88.8%
(n=2869)
84.4%
(n=895)
79%
(n=9827)
73.4%
(n=3098)
<0.001
Normal  coronary  angiogram
8.1%
(n=1179)
14.7%
(n=770)
2.7%
(n=245)
8.4%
(n=254)
3%
(n=104)
7.2%
(n=82)
5.7%
(n=1528)
11.7%
n=1106)
<0.001
No.  of  vessels  with  >50%  stenosis
0 8.5%
(n=1240)
15.1%
(n=786)
5.3%
(n=418)
12.8%
(n=340)
4.8%
(n=143)
10.8%
(n=106)
7.1%
(n=1801)
13.9%
(n=1232)
<0.001
1 39.5%  (n=5746)  37.4%  (n=1950)  42.2%  (n=3316)  41.6%  (n=1109)  43.7%  (n=1310)  43.3%  (n=426)  40.9%
(n=10  372)
39.3%  (n=3485)  0.009
2 27.1%  (n=3939)  22.9%  (n=1194)  27.7%  (n=2175)  25.2%  (n=671)  29%  (n=868)  26.4%  (n=260)  27.5%  (n=6982)  24%  (n=2125)  <0.001
3 24.8%  (n=3605)  24.7%  (n=1290)  24.7%  (n=1941)  20.4%  (n=544)  22.6%  (n=677)  19.5%  (n=192)  24.5%  (n=6223)  22.8%  (n=2026)  0.001
Location of  vessels  with  >50%  stenosis
LM  6.1%  (n=880)  5.9%  (n=390)  8.8%  (n=677)  6.7%  (n=177)  8.1%  (n=241)  5.9%  (n=57)  7.1%  (n=1798)  6.2%  (n=543)  0.002
LAD 64.5%
(n=9389)
62.7%
(n=3278)
65.4%
(n=5576)
64.1%
(n=1856)
67.1%
(n=2190)
65.1%
(n=710)
65.1%
(n=17  155)
63.4%
(n=5844)
0.003
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Table  9  (Continued)
2002-2010  2011-2015  2016-2019  2002-2019
Men
(n=20  995)
Women
(n=9051)
Men
(n=10  020)
Women
(n=3760)
Men
(n=3921)
Women
(n=1366)
Men
(n=34  936)
Women
(n=14  177)
p
Cx  47.3%
(n=6879)
43.1%
(n=2249)
49.7%
(n=4100)
41.6%
(n=1149)
46.9%
(n=1481)
41.5%
(n=424)
48%
(n=12  460)
42.4%
(n=3822)
<0.001
RCA 53.6%
(n=7798)
48.9%
(n=2558)
56.9%
(n=4767)
50.6%
(n=1438)
57.4%
(n=1851)
50.3%
(n=526)
55.1%
(n=14  416)
49.6%
(n=4522)
<0.001
Bypass 66.2%
(n=387)
66.2%
(n=102)
54.7%
(n=220)
63.3%
(n=50)
54.7%
(n=75)
45.8%
(n=11)
60.7%
(n=682)
63.4%
(n=163)
0.415
Multivessel  disease
Culprit  lesion 52%
(n=7556)
47.6%
(n=2489)
54.6%
(n=4499)
47.6%
(n=1319)
54%
(n=1704)
48.1%
(n=493)
53.1%
(n=13  759)
47.7%
(n=4301)
<0.001
LM 1.5%
(n=180)
1.4%
(n=57)
1.8%
(n=139)
1.3%
(n=32)
2%
(n=57)
2%
(n=17)
1.7%
(n=376)
1.5%
(n=106)
0.187
LAD  38.4%  (n=4578) 39.5%  (n=1572) 36.3%  (n=2764) 40.6%  (n=982) 40.8%  (n=1141) 45.5%  (n=395) 38%  (n=8483) 40.5%  (n=2949) <0.001
Cx 15.7%  (n=1870) 14.4%  (n=574) 17%  (n=1298) 14.3%  (n=347) 16.7%  (n=467) 15.2%  (n=132) 16.3%  (n=3635) 14.5%  (n=1053) <0.001
RCA 24.7%
(n=2950)
23.3%
(n=929)
27.6%
(n=2102)
26%
(n=630)
30.4%
(n=850)
27.2%
(n=236)
26.4%
(n=5902)
24.7%
(n=1795)
0.003
Graft  1.3%
(n=156)
0.8%
(n=30)
1.5%
(n=115)
0.9%
(n=21)
1.6%
(n=44)
0.6%
(n=5)
1.4%
(n=315)
0.8%
(n=56)
<0.001
Unknown  18.3%
(n=2187)
20.6%
(n=822)
15.8%
(n=1202)
16.9%
(n=409)
8.6%
(n=240)
9.6%
(n=83)
16.2%
(n=3629)
18.1%
(n=1314)
<0.001
Cx: circumflex artery; LAD: left anterior descending artery; LM: left main; PCI: percutaneous coronary intervention; RCA: right coronary artery
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Table  10  Pharmacological  therapy  during  hospitalization  and  at  hospital  discharge.
During  hospitalization  At  discharge
Men
(n=34  936)
Women
(n=14  177)
p  Men
(n=32  171)
Women
(n=12  748)
p
Aspirin  97.7%
(n=33  745)
96.8%
(n=13  574)
<0.001  94.1%
(n=30273)
91.7%
(n=11690)
<0.001
Clopidogrel  67.6%
(n=23  160)
62.5%
(n=8681)
<0.001  60.4%
(n=19  183)
54.1%
(n=6803)
<0.001
Prasugrela 0.1%  (n=9)  0.1%
(n=2)
0.738  0.3%
(n=23)
0.2%
(n=7)
0.606
Ticagrelora 24.4%
(n=2850)
20.1%
(n=850)
<0.001  22.8%
(n=2477)
17.9%
(n=693)
<0.001
Other
antiplatelets
5%
(n=1702)
4.5%
(n=6269
0.036  5.8%  (n=1830)  5.6%  (n=700)  0.413
Eptifibatide 42.5%
(n=3434)
39.3%
(n=975)
0.005  N/A  N/A  N/A
Tirofiban 32.6%
(n=2633)
39.5%
(n=980)
<0.001  N/A  N/A  N/A
Abciximab 25%
(n=2022)
21.3%
(n=529)
<0.001  N/A  N/A  N/A
UFH 25.8%
(n=8795)
20.7%
(n=2858)
<0.001  N/A  N/A  N/A
LMWH 65.3%
(n=22  048)
68%
(n=9331)
<0.001  N/A  N/A  N/A
VKA 2.5%
(n=360)
2.8%
(n=149)
0.254  4.2%
(n=561)
5.3%
(n=260)
0.001
Dabigatrana 0.4%
(n=38)
0.2%
(n=6)
0.037  1.2%
(n=108)
1.5%
(n=48)
0.216
Other  OACa 0.8%
(n=109)
0.7%
(n=39)
0.847  3%
(n=396)
3.3%
(n=163)
0.207
Beta-blockers  77.1%
(n=26  589)
72.5%
(n=10  118)
<0.001  75.6%
(n=24  294)
71%
(n=9049)
<0.001
ACEIs/ARBsa 79.4%
(n=27  426)
80.1%
(n=11  237)
0.064  77.4%
(n=24  930)
76.7%
(n=9805)
0.09
Statins  90.8%
(n=31  393)
87.5%
(n=12  268)
<0.001  91.7%
(n=29  580)
88%
(n=11  255)
<0.001
Nitrates 65.4%
(n=22  554)
70.2%
(n=9835)
<0.001  37.7%
(n=12  008)
45.6%
(n=5770)
<0.001
Ivabradinea 3.8%
(n=550)
4.5%
(n=242)
0.024  4.2%
(n=569)
4.5%
(n=222)
0.419
MRAsa 10.9%
(n=1567)
13.4%
(n=715)
<0.001  10%
(n=1341)
11.9%
(n=583)
<0.001
Diureticsa 25.6%
(n=3695)
38.8%
(n=2074)
<0.001  22.6%
(n=3033)
34.2%
(n=1684)
<0.001
Amiodaronea 6.6%
(n=957)
9.6%
(n=516)
<0.001  3.4%
(n=451)
5.3%
(n=263)
<0.001
Inotropes  5%
(n=1711)
7.8%
(n=1076)
<0.001  NA  N/A  N/A
Insulina 24.7%
(n=3562)
31.5%
(n=1682)
<0.001  5.4%
(n=722)
10.4%
(n=513)
<0.001
OADa 6.6%
(n=951)
8.1%
(n=433)
<0.001  19.5%
(n=2622)
23.5%
(n=1157)
<0.001
a variable included only after October 2010.
ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; LMWH: low molecular weight heparin; MRAs:
mineralocorticoid receptor antagonists; OAC: oral anticoagulants; OAD: antidiabetic therapy; UFH: unfractionated heparin; VKA: vitamin
K antagonist.
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Table  11  Complications  during  hospitalization.
Men  Women  OR  (95%  CI)  p
Reinfarction  1.2%
(n=421)
1.4%
(n=204)
1.20  (1.01-1.42)  0.036
HF 19.4%
(n=5807)
31.1%
(n=3739)
1.87  (1.78-1.97) <0.001
Cardiogenic  shock  4.3%
(n=1273)
7.1%
(n=851)
1.71  (1.57-1.87)  <0.001
Invasive mechanical
ventilation
2.3%
(n=787)
2.5%
(n=360)
1.13  (1.00-1.28)  0.057
Non-invasive
ventilationa
1.9%
(n=284)
2.7%
(n=145)
1.39  (1.14-1.70)  0.001
AFa 4.4%
(n=638)
6.6%
(n=357)
1.55  (1.36-1.77)  <0.001
Mechanical
complications
0.8%
(n=274)
1.7%
(n=234)
2.12  (1.78-2.53)  <0.001
AV block  2.8%
(n=273)
3.6%
(n=514)
1.31  (1.18-1.46)  <0.001
Temporary
pacemakera
1.6%
(n=234)
2.7%
(n=143)
1.67  (1.35:2.06))  <0.001
Sustained VTa 1.7%
(n=252)
1.7%
(n=91)
0.98  (0.77-1.24)  0.84
Cardiac arrest  2.8%
(n=964)
2.4%
(n=342)
0.87  (0.77-0.99)  0.03
Stroke 0.6%
(n=208)
1.3%
(n=180)
2.15  (1.76-2.62)  <0.001
Major bleeding  1.1%
(n=400)
1.7%
(n=247)
1.53  (1.30-1.80)  <0.001
Blood transfusiona 1.2%
(n=179)
3.1%
(n=168)
2.59  (2.09-3.20)  <0.001
Death 3.7%
(n=1288)
6.9%
(n=982)
1.94  (1.78-2.12)  <0.001
a
 HF: 
f
l
i
l
l
d
i
i
t
a
p
s
a
à
a
t
t
Pvariable included only after October 2010.
AF:atrial fibrillation; AV: atrioventricular; CI: confidence interval;
European  Cardiovascular  Disease  Statistics,  CVD  is  respon-
sible  for  3.9  million  deaths  in  Europe,  accounting  for  45%
of  all  deaths,  and  is  the  leading  cause  of  death  in  women
in  all  except  two  countries.  The  largest  gap  in  mortality  by
gender  is  found  in  the  Baltic  states,  Slovenia  and  Romania,
where  the  percentage  of  women  dying  from  cardiovascular
diseases  is  13.5-17.4%  higher  than  in  men.6 Another  Euro-
pean  analysis  from  2015  shows  that  the  difference  between
the  sexes  is  more  marked  regarding  ischemic  heart  disease
(IHD);  however,  unlike  in  all  CVD,  the  mortality  rate  from  IHD
is  1.8  times  higher  in  men.7 Our  results  show  that  in  Portugal,
although  published  data  from  the  ProACS  indicate  that  in-
hospital  mortality  has  declined  steadily  since  2002,8 in  the
period  studied,  among  patients  admitted  to  hospital  with
ACS  women  were  more  likely  to  die  than  men.  This  appar-
ent  difference  in  results  may  be  due  to  the  fact  that  official
European  data  analyze  overall  mortality  from  IHD  (which
includes  a  spectrum  of  disease)  over  time,  unlike  our  work,
in  which  we  assessed  a  single  event  in  the  continuum  of  IHD
and  associated  in-hospital  mortality.  However,  it  should  bePlease  cite  this  article  in  press  as:  Roque  D,  et  al.  Understandin
coronary  syndrome.  Rev  Port  Cardiol.  2020.  https://doi.org/10
borne  in  mind  that  this  higher  mortality  is  unadjusted  for
other  variables,  and  in  a  report  from  China,  in  which  unad-
justed  in-hospital  mortality  for  women  initially  appeared
to  be  higher,  this  was  no  longer  the  case  after  adjustment
a
l
p
rheart failure; OR: odds ratio; VT: ventricular tachycardia.
or  clinical  characteristics  and  acute  treatments.9 A  simi-
ar  result  was  seen  in  a  study  on  patients  from  the  ProACS,
n  which  after  propensity  score  adjustment,  gender  was  no
onger  a  predictor  of  in-hospital  mortality.2
When  traditional  cardiovascular  risk  factors  were  ana-
yzed,  there  was  a  higher  prevalence  of  hypertension,
yslipidemia,  diabetes  and  obesity  and  a  growing  prevalence
n  the  periods  studied  of  smoking,  diabetes  and  dyslipidemia
n  women,  showing  that  the  efforts  of  the  health  community
o  call  attention  to  the  need  for  better  risk  factor  control
re  still  insufficient,  since  despite  the  growing  number  of
atients  at  hospital  admission  who  are,  for  example,  pre-
cribed  antihypertensive  and  statin  therapy,  these  patients
re  still  lower  in  number  than  those  diagnosed  with  ACS
 despite  the  growing  number  of  patients  that  at  hospital
dmission  are,  for  example,  treated  with  anti-hypertensive
herapy  and  statins;  those  are  still  in  lower  number  than
hose  with  the  diagnosis.
Data  from  the  US  Centers  for  Disease  Control  and
revention  show  that  women  are  less  likely  to  be  prescribedg  a woman’s  heart:  Lessons  from  14  177  women  with  acute
.1016/j.repc.2020.03.002
 statin,  and  that  their  therapeutic  adherence  is  also
ow.10,11 In  terms  of  secondary  prevention,  a  meta-analysis
erformed  by  the  Cholesterol  Treatment  Trialists’  Collabo-
ation  with  170  000  patients  from  statin  trials  shows  that  a
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4  
eduction  of  38.66  mg/dl  in  LDL  cholesterol  is  associated
ith  a  22%  relative  risk  reduction  in  major  vascular  events,
he  results  being  similar  for  both  sexes.12 Despite  this  evi-
ence,  in  our  study  women  were  undertreated  with  statins
oth  during  hospitalization  and  at  discharge,  even  though
he  prevalence  of  dyslipidemia  is  higher  in  women.  It  is
nclear  whether  this  is  due  to  a  higher  prevalence  of  adverse
ffects  of  statins  in  women  than  in  men,  but  it  probably  sig-
als  the  need  for  greater  physician  and  patient  awareness.
Hypertension  is  more  strongly  associated  with  MI  in
omen  than  in  men.13 Furthermore,  pregnancy-related
omplications  such  as  pre-eclampsia  and  gestational  hyper-
ension  are  associated  with  a  greater  long-term  risk  of
eveloping  hypertension  and  CVD,  and  postmenopausal
omen  are  also  more  likely  to  have  a  non-dipper  pat-
ern,  which  has  been  associated  with  worse  cardiovascular
utcomes  and  target  organ  damage.14,15 There  is  no  evi-
ence  that  antihypertensive  therapy  has  a  different  efficacy
r  safety  profile  in  women,  even  though  most  trials
o  not  analyze  their  data  by  gender.  In  our  study,  we
ound  no  differences  in  the  prescription  of  angiotensin-
onverting  enzyme  inhibitors/angiotensin  receptor  blockers
ACEIs/ARBs)  between  genders,  either  during  hospitalization
r  at  discharge,  but  the  rate  of  beta-blocker  prescription
as  higher  in  men  at  both  times.  The  prescription  of  other
ntihypertensive  therapy  during  hospitalization  or  at  dis-
harge  is  unknown.
Compared  to  women  without  diabetes,  those  with  dia-
etes  have  a  three-fold  higher  risk  of  fatal  CAD,  and  their
isk  is  also  higher  than  in  men  with  diabetes.  Women  with
iabetes  have  a  more  aggressive  profile  of  CAD,  related  to
reater  impairment  of  endothelium-dependent  vasodilation
nd  greater  likelihood  of  hypercoagulable  states,  athero-
enic  dyslipidemia,  and  metabolic  syndrome.  Considering
hat  the  harmful  effects  of  glucose  begin  to  occur  at  blood
lucose  levels  lower  than  those  currently  accepted  for  a
iagnosis  of  diabetes,  the  transition  from  normoglycemia  to
lucose  intolerance  and  diabetes  may  be  more  detrimen-
al  in  women.16--18 Although  there  was  no  difference  in  the
ate  of  prescription  of  insulin  or  oral  antidiabetic  therapy
etween  the  sexes  before  hospital  admission,  during  hospi-
alization  and  at  hospital  discharge  there  were  significant
ifferences,  combined  with  the  underdiagnosis  of  diabetes
n  outpatients  and/or  undertreatment.
Smoking  is  the  most  important  preventable  cause  of  MI
n  women,  and  a  major  risk  factor  for  women  aged  <55
ears,  leading  to  an  increase  in  the  risk  of  MI.  Although
here  has  been  an  overall  reduction  in  the  use  of  tobacco
roducts  in  the  US,  this  decline  is  considerably  less  marked
n  women,19,20 which  agrees  with  our  data.
The  prevalence  of  obesity  is  higher  in  women,  as  well  as
he  impact  that  this  risk  factor  has  on  the  development  of
AD.  In  the  Framingham  Heart  Study,  obesity  increased  the
elative  risk  of  CAD  by  64%  for  women  (vs.  46%  for  men).
espite  this  knowledge,  the  prevalence  of  obesity  in  women
ith  ACS  is  still  higher  than  in  men.21 Additionally,  women
ave  other  non-traditional  risk  factors  that  are  not  analyzed
n  our  study,  such  as  depression,  premature  labor,  radiother-Please  cite  this  article  in  press  as:  Roque  D,  et  al.  Understandin
coronary  syndrome.  Rev  Port  Cardiol.  2020.  https://doi.org/10
py  for  breast  cancer,  and  many  chemotherapy  drugs.
It  is  increasingly  recognized  that  CAD  in  women  is  not
estricted  to  obstructive  atherosclerotic  coronary  disease,
ut  also  includes  microvascular  and  endothelial  dysfunction,
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oronary  vasomotor  abnormalities,  and  spontaneous  coro-
ary  artery  dissection.  This  extended  spectrum  of  a  single
isease  creates  difficulties  not  only  in  diagnosis  but  also
n  treatment,  resulting  in  women  frequently  being  under-
iagnosed  and  undertreated  if  they  do  not  present  with  the
ypical  pattern  of  obstructive  coronary  atherosclerosis.22
his  is  a  possible  explanation  for  our  finding  of  a  sig-
ificant  difference  between  the  sexes  regarding  coronary
ngiograms  with  normal  coronary  arteries  or  with  <50%
tenosis,  which  reflects  a  well-known  paradox:  women  had
 higher  prevalence  than  men  of  stable  angina  pre-hospital
dmission  (29.1%  vs.  23.8%,  p<0.001)  and  less  likelihood  of
bstructive  CAD  on  coronary  angiography  (5.7%  vs.  11.7%,
<0.001)  but  a  worse  prognosis  (in-hospital  mortality  6.9%
s.  3.7%,  p<0.001).  In  addition  to  this,  pathology  and  image
tudies  have  shown  that  women  have  smaller  coronary  arter-
es,  a  more  diffuse  pattern  of  atherosclerosis  with  fewer
bstructive  lesions,  and  a  greater  incidence  of  plaque  ero-
ion  as  the  substrate  of  acute  thrombosis.23 This  paradox  of
ess  obstructive  CAD  with  worse  outcomes  can,  at  least  in
art,  be  explained  by  the  connection  between  microvascu-
ar  disease  and  coronary  atherosclerosis;  in  addition,  there
s  increasing  evidence  that  more  extensive  non-obstructive
AD  is  associated  with  a  similar  rate  of  adverse  cardiovas-
ular  outcomes  to  obstructive  CAD.24
With  regard  to  clinical  presentation  of  ACS,  our  results
onfirm  what  was  previously  known:  women  more  frequently
ave  atypical  symptoms,  even  though  the  most  common
resenting  symptom  is  still  chest  pain.25,26 This  gender
ifference  in  clinical  presentation  affects  the  timely  iden-
ification  of  ischemic  symptoms,  appropriate  triage,  and
herapeutic  approach,  leading  to  delays  in  revascularization
nd  higher  mortality.  In  a  study  in  France,  all  the  timings
ere  longer  in  women;  in-hospital  morbidity  and  mortality
ates  were  also  significantly  higher,  and  rates  of  prescrip-
ion  of  guideline-recommended  therapies  were  lower.27 Our
esults  are  in  line  with  these  findings  and  those  of  similar
tudies,  and  all  the  timings  analyzed  were  longer  in  women,
egardless  of  whether  the  starting  point  was  symptom  onset,
MC  or  arrival  at  the  door.  However,  comparing  the  two
ore  recent  periods,  FMC-to-needle,  door-to-needle  and
ymptom  onset-to-balloon  times  improved  in  women,  unlike
n  men,  and  in  both  sexes  there  were  improvements  in
MC-to-balloon,  door-to-wire  crossing,  door-to-balloon,  and
MC-to-wire  crossing  times.  On  the  other  hand,  in  these
wo  more  recent  periods,  longer  times  were  observed  in
omen  from  symptom  onset  to  admission,  wire  crossing  and
eedle,  as  well  as  from  FMC  to  admission,  leading  to  the
onclusion  that  overall,  although  after  FMC  and/or  hospital
dmission  the  path  to  treatment  is  becoming  more  effi-
ient,  the  female  population  do  not  seem  to  be  aware  of
he  need  for  timely  recognition  of  the  signs  and  symptoms
f  MI,  leading  to  greater  delays,  particularly  in  patient-
ependent  times.  A  similar  discrepancy  has  been  observed
n  other  countries,  including  New  Zealand,  Australia,  France
nd  the  USA.27--29 Another  important  point  is  the  paradoxi-
ally  greater  delays  in  STEMI  quality  indices  when  the  period
002-2010  is  compared  to  the  two  more  recent  periods.g  a  woman’s  heart:  Lessons  from  14  177  women  with  acute
.1016/j.repc.2020.03.002
he  mortality  benefit  achieved  with  primary  PCI  in  STEMI
atients  is  reduced  by  treatment  delays,30 and  mortality
ell  between  these  periods.8 This  paradox  was  addressed  in
 Portuguese  study  from  2017,8 in  which  the  authors  state
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that,  while  there  have  been  improvements  in  centers  with  a
catheterization  laboratory,  with  the  proportion  of  patients
with  door-to-balloon  time  <60  min  rising  from  52.5%  to  73.5%
(86.1%  <90  min),  in  centers  without  PCI  facilities,  the  timings
vary  widely  over  the  years,  and  were  <60  min  in  only  14.6%,
<90  min  in  22.4%  and  <120  min  in  36.5%.  In  addition,  there
was  considerable  variability  in  the  first  years  of  the  registry
in  centers  without  PCI  facilities,  associated  with  the  smaller
number  of  patients  in  these  groups.  This  variability  in  the
first  years  of  the  registry  and  the  differences  between  cen-
ters  with  and  without  PCI  facilities  may  be  partly  responsible
for  the  paradox.
The  high  risk  profile  of  women  undergoing  primary  angio-
plasty,  in  terms  of  both  ischemic  risk  (as  shown  by  the  GRACE
score)  and  bleeding  risk  (as  shown  by  the  CRUSADE  score),
is  reflected  in  a  higher  proportion  of  no  or  non-significant
coronary  lesions  in  our  study,  less  extensive  CAD  and  a  lower
prevalence  of  multivessel  disease  on  coronary  angiography
in  women  compared  with  men.  These  findings  are  similar
to  those  of  a  previous  study  in  which  the  authors  showed
that  despite  the  higher  risk  profile  of  women,  there  were
no  differences  between  the  sexes  in  the  extent  of  coronary
disease  or  the  prevalence  of  multivessel  disease.2 It  should
be  borne  in  mind,  however,  that  this  risk  profile  is  essen-
tially  a  clinical  assumption,  considering  that  in  ACS  little
is  known  regarding  the  prognostic  factors  for  adverse  out-
comes  in  women,  and,  although  several  risk  scores  such  as
GRACE  and  TIMI  are  commonly  used,  these  were  developed
based  on  populations  of  which  two-thirds  were  male,  and  so
their  performance  in  women  is  not  well  established.22
Despite  the  clear  recommendation  in  the  guidelines  for
radial  access  as  the  preferred  mode  of  access,  and  the  higher
bleeding  risk  of  women,  our  data  indicate  that  this  arterial
route  is  less  used  in  women,  even  though  a  substudy  of  the
MATRIX  trial  showed  that  women  have  greater  risk  of  severe
bleeding  and  access  complications,  and  that  radial  access  is
an  effective  way  of  reducing  these  complications.31
Even  after  adjusting  for  factors  like  age,  comorbidities
and  disease  severity,  several  studies  have  shown  that  women
are  less  likely  to  be  given  recommended  therapies  either  at
hospital  admission  or  at  hospital  discharge,  including  beta-
blockers,  ACEIs/ARBs,  and  statins.27,32,33 Our  results  indicate
that  for  ACEIs/ARBs  the  prescription  rate  is  similar  to  men
(unlike  statins  and  beta-blockers),  which  itself  may  repre-
sent  under-prescription,  considering  the  higher  risk  profile
of  women,  as  demonstrated  by  the  fact  that  women  have
more  complications,  such  as  sustained  VT  or  the  need  for
non-invasive  ventilation,  even  though  they  have  less  exten-
sive  CAD.34 Factors  that  may  contribute  to  this  finding  in
women  are  their  higher  rates  of  diabetes,  hypertension,
and  obesity,  a  higher  prevalence  of  outpatient  HF,  delays
between  symptom  onset  and  reperfusion  therapy,  a  higher
prevalence  of  acute  kidney  injury,  and  the  fact  that  they  may
less  frequently  be  offered  reperfusion  therapy  and  medica-
tion  for  secondary  prevention.
LimitationsPlease  cite  this  article  in  press  as:  Roque  D,  et  al.  Understandin
coronary  syndrome.  Rev  Port  Cardiol.  2020.  https://doi.org/10
The  observational  nature  of  this  study  means  that  we  cannot
exclude  the  existence  of  possible  additional  confounders
that  are  not  identified  or  accounted  for  in  the  data  analysis. PRESS
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urthermore,  although  the  data  from  ProACS  is  largely  rep-
esentative  of  the  various  geographic  regions  of  Portugal,
t  is  not  possible  to  infer  conclusions  about  the  country  as
 whole.  As  the  registry  is  voluntary,  it  is  not  possible  to
nsure  that  patients  were  included  consecutively;  some  ACS
atients  were  not  hospitalized  in  cardiology  departments
nd  therefore  are  not  included  in  the  database;  and  only
atients  who  were  admitted  alive  are  included,  and  so
 proportion  of  patients  with  fatal  complications  before
dmission  were  omitted  from  the  analysis.  In  addition,  the
umber  of  records  has  decreased  in  recent  years,  which
ay  have  led  to  bias  when  comparing  periods,  and  as  the
egistry  is  voluntary,  some  data  may  have  been  missed,
eading  to  data  inconsistencies.  Another  limitation  of  our
tudy  is  that  some  data  were  only  collected  after  October
010,  and  so  a  considerable  number  of  patients  did  not
ave  all  of  their  parameters  recorded.
onclusion
he  number  of  women  with  CAD  is  increasing;  however,
ompared  with  men,  this  disease  is  still  underdiagnosed
nd  undertreated,  and  women  have  less  access  to  revas-
ularization  and  optimal  medical  therapy.  Although  in  the
verall  population  a  significant  increase  in  the  use  of  PCI
as  observed,  there  is  still  a  statistically  significant  differ-
nce  in  its  use  between  the  sexes;  women  are  less  likely  to
eceive  guideline-recommended  therapy  in  the  context  of
econdary  prevention,  even  in  the  most  recent  time  period;
nd  in-hospital  complications  and  unadjusted  mortality  are
till  higher  in  women,  despite  improvements  in  overall  mor-
ality  over  the  years.  These  findings  are  based  on  a  voluntary
egistry  and  the  inherent  limitations  should  be  borne  in
ind.
Greater  awareness  of  both  patients  and  health  profes-
ionals  is  urgently  needed  to  change  the  way  ACS  is  treated
n  women.
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